These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20183956)

  • 41. The changing profile of the cardiovascular patient and the future of cardiovascular disease treatment and prevention: British Columbia as an example.
    Ignaszewski AP; Ignaszewski MJ
    Kardiol Pol; 2011; 69(10):1099-103. PubMed ID: 22006622
    [No Abstract]   [Full Text] [Related]  

  • 42. Trialogue Plus: Management of cardiovascular risk in hyperglycaemic/diabetic patients at hospital discharge.
    Beltramello G; Manicardi V; Mazzuoli F; Rivellese A;
    Acta Diabetol; 2013 Dec; 50(6):989-98. PubMed ID: 24121870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    Matthys F; De Backer T; De Backer G; Stichele RV
    Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective.
    Tomé-Carneiro J; Gonzálvez M; Larrosa M; Yáñez-Gascón MJ; García-Almagro FJ; Ruiz-Ros JA; Tomás-Barberán FA; García-Conesa MT; Espín JC
    Ann N Y Acad Sci; 2013 Jul; 1290():37-51. PubMed ID: 23855464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds.
    Kolber MR; Korownyk C
    Expert Opin Pharmacother; 2014 Feb; 15(2):153-7. PubMed ID: 24206142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating cardiovascular disease in women.
    Taggu W; Lloyd G
    Menopause Int; 2007 Dec; 13(4):159-64. PubMed ID: 18088527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Strategies for cardiovascular prevention in women].
    Leuzzi C; Modena MG
    G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):93S-96S. PubMed ID: 20879491
    [No Abstract]   [Full Text] [Related]  

  • 48. Global cardiovascular risk management in different Italian regions: an analysis of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation (EFFECTUS) educational program.
    Tocci G; Ferrucci A; Guida P; Corsini A; Avogaro A; Comaschi M; Cortese C; Giorda CB; Manzato E; Medea G; Mureddu GF; Titta G; Ventriglia G; Riccardi G; Zito GB; Volpe M
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):635-42. PubMed ID: 21186104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapeutic Strategies. Cardiovascular risk and dyslipidemia in elderly and women].
    Morales C; Royuela M
    Clin Investig Arterioscler; 2013; 25(3):146-50. PubMed ID: 23786854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with myocardial infarction.
    Chin BS; Kharim S; Ghaffar A; Rehman A; Lip GY
    J Intern Med; 2001 Aug; 250(2):180-2. PubMed ID: 11489070
    [No Abstract]   [Full Text] [Related]  

  • 51. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
    Dehghan M; Mente A; Teo KK; Gao P; Sleight P; Dagenais G; Avezum A; Probstfield JL; Dans T; Yusuf S;
    Circulation; 2012 Dec; 126(23):2705-12. PubMed ID: 23212996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome.
    Lafitte M; Pradeau V; Leroux L; Richeboeuf V; Tastet S; Boulon C; Paviot B; Bonnet J; Couffinhal T
    Arch Cardiovasc Dis; 2009 Jan; 102(1):51-8. PubMed ID: 19233109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EJPC @ a glance: focus issue on cardiovascular risk prediction in primary and secondary prevention.
    Tsaban G; Aboyans V
    Eur J Prev Cardiol; 2024 Oct; 31(14):1668-1670. PubMed ID: 39270738
    [No Abstract]   [Full Text] [Related]  

  • 54. Principles for national and regional guidelines on cardiovascular disease prevention.
    Smith S; Voûte J; Fuster V
    Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):461. PubMed ID: 16932757
    [No Abstract]   [Full Text] [Related]  

  • 55. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging clinical challenges in the use of statins.
    Hennekens CH; Breuer NR; Gelb IJ; Bjorkman DJ; Borer JS; Pfeffer MA
    Am J Med; 2013 Aug; 126(8):663-4. PubMed ID: 23786669
    [No Abstract]   [Full Text] [Related]  

  • 57. Secondary prevention of cardiovascular disease: Unmet medical need, implementation and innovation.
    Grobbee DE; Pellicia A
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):5-7. PubMed ID: 28618911
    [No Abstract]   [Full Text] [Related]  

  • 58. Cardioprotective Exercise and Pharmacologic Interventions as Complementary Antidotes to Cardiovascular Disease.
    Quindry JC; Franklin BA
    Exerc Sport Sci Rev; 2018 Jan; 46(1):5-17. PubMed ID: 28885265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Future of polypill use for the prevention of cardiovascular disease and strokes.
    Chrysant SG; Chrysant GS
    Am J Cardiol; 2014 Aug; 114(4):641-5. PubMed ID: 24996555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.